A three-gene panel consisting of HOXC6, TDRD1, and DLX1 [87] was also found to significantly improve the detection of clinically-significant prostate cancer with an AUC of 0.77 when compared to PSA (AUC 0.72) and PCA3 (AUC 0.68) Van Neste et al. recently validated and compared these markers with other urine-based prostate cancer gene markers [88]. This evidence concerns the gene TDRD1 and Familial prostate cancer.